
|Videos|November 21, 2017
Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer
Author(s)Josh H. Heinzerling, MD
Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.
Advertisement
Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.
There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.
According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
5






























































